Autres langues DYNC SPL

Actions

DYNS

US2680101050

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 24/04/2024			Varia. 5j.	Varia. 1 janv.
0,2809 ^USD	-6,37 %		-9,39 %	-96,26 %

2022	Senti Biosciences achève son regroupement d'entreprises et commencera à se négocier au Nasdaq jeudi.	MT
2022	Senti Biosciences, Inc. a achevé l'acquisition de Dynamics Special Purpose Corp. (NasdaqCM:DYNS) auprès d'un groupe d'actionnaires dans le cadre d'une opération de fusion inversée.	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

DYNC SPL : SENTI BIOSCIENCES, INC. INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Form 8-K	15/06/22
Senti Biosciences Completes Business Combination, Will Begin Trading on Nasdaq Thursday	09/06/22
DYNC SPL : Senti Bio Debuts as Publicly Traded Company Focused on Developing Next-Generation Cell and Gene Therapies Engineered with Gene Circuits - Form 8-K	09/06/22
DYNAMICS SPECIAL PURPOSE CORP. : Other Events, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	09/06/22
Senti Bio Debuts as Publicly Traded Company Focused on Developing Next-Generation Cell and Gene Therapies Engineered with Gene Circuits	09/06/22
Dynamics Special Purpose Corp.(NasdaqCM:DYNS) dropped from NASDAQ Composite Index	08/06/22
Senti Biosciences, Inc. completed the acquisition of Dynamics Special Purpose Corp. from a group of shareholders in a reverse merger transaction.	08/06/22
DYNAMICS SPECIAL PURPOSE CORP. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Other Events (form 8-K)	07/06/22
Dynamics Special Purpose Corp. has Changed its Name to Senti Biosciences, Inc	07/06/22
Dynamics Special Purpose Corp. Approves Board Elections	07/06/22
Dynamics Special Purpose : Senti Bio Names Dr. Kanya Rajangam to Newly Created Position of Chief Medical and Development Officer - Form 8-K	25/05/22
DYNAMICS SPECIAL PURPOSE CORP. : Other Events, Financial Statements and Exhibits (form 8-K)	25/05/22
Leaps by Bayer led Series B investment in Senti Bio in 2021; Additional Convertible Note financing expands committed capital to PIPE investment associated with previously announced Business Combination Agreement with DYNS - - DYNS announces effectiveness of registration statement on Form S-4 - - Meeting of DYNS stockholders to approve proposed business combination scheduled for Tuesday, June 7, 2022 at 10:00 a.m. ET - Form 8-K	24/05/22
DYNAMICS SPECIAL PURPOSE CORP. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	24/05/22
DYNAMICS SPECIAL PURPOSE CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	16/05/22
Dynamics Special Purpose Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22
DYNAMICS SPECIAL PURPOSE CORP. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	10/05/22
SPACs splash the cash to salvage deals as market unravels	16/03/22
DYNAMICS SPECIAL PURPOSE CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	07/03/22
Dynamics Special Purpose Corp. Reports Earnings Results for the Ten Months Ended December 31, 2021	07/03/22

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues DYNC SPL

Actions

DYNS

US2680101050

Autres langues

Filtres